Bub3 reads phosphorylated MELT repeats to promote spindle assembly checkpoint signaling
|
journal
|
September 2013 |
Phosphodependent Recruitment of Bub1 and Bub3 to Spc7/KNL1 by Mph1 Kinase Maintains the Spindle Checkpoint
|
journal
|
May 2012 |
MPS1/Mph1 phosphorylates the kinetochore protein KNL1/Spc7 to recruit SAC components
|
journal
|
June 2012 |
Mps1 Phosphorylates Borealin to Control Aurora B Activity and Chromosome Alignment
|
journal
|
January 2008 |
Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs
|
journal
|
August 2013 |
High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells
|
journal
|
March 2011 |
Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715
|
journal
|
November 2013 |
Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores
|
journal
|
June 2008 |
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
|
journal
|
August 2006 |
Inhibition of mitotic kinase Mps1 promotes cell death in neuroblastoma
|
journal
|
July 2020 |
Targeting the Mitotic Checkpoint to Kill Tumor Cells
|
journal
|
December 2010 |
Characterization of novel MPS1 inhibitors with preclinical anticancer activity
|
journal
|
August 2013 |
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
|
journal
|
April 2020 |
Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d ]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N 2 -(2-Ethoxy-4-(4-methyl-4 H -1,2,4-triazol-3-yl)phenyl)-6-methyl- N 8 -neopentylpyrido[3,4- d ]pyrimidine-2,8-diamine (BOS172722)
|
journal
|
September 2018 |
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer
|
journal
|
March 2017 |
Kinase Drug Discovery – What’s Next in the Field?
|
journal
|
December 2012 |
Drug–target residence time and its implications for lead optimization
|
journal
|
August 2006 |
Binding Kinetics Survey of the Drugged Kinome
|
journal
|
October 2018 |
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity
|
journal
|
July 2017 |
Pharmacokinetics and the drug–target residence time concept
|
journal
|
August 2013 |
The resurgence of covalent drugs
|
journal
|
April 2011 |
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
|
journal
|
June 2012 |
The Cysteinome of Protein Kinases as a Target in Drug Development
|
journal
|
February 2018 |
Advances in covalent kinase inhibitors
|
journal
|
January 2020 |
Chemical Probes for Understudied Kinases: Challenges and Opportunities
|
journal
|
September 2021 |
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
|
journal
|
March 2021 |
Mobocertinib: First Approval
|
journal
|
October 2021 |
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
|
journal
|
December 2018 |
Covalent inhibitors: back on track?
|
journal
|
August 2020 |
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
|
journal
|
March 2015 |
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
|
journal
|
October 2019 |
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
|
journal
|
December 2017 |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
|
journal
|
August 2019 |
Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)
|
journal
|
October 2021 |
Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase
|
journal
|
December 2010 |
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective
|
journal
|
August 2019 |
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors
|
journal
|
February 2021 |
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function
|
journal
|
April 2010 |
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
|
journal
|
October 2015 |
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
|
journal
|
December 1973 |
Mechanism-Based Inhibition: Deriving K I and k inact Directly from Time-Dependent IC 50 Values
|
journal
|
August 2009 |
Covalent inhibitors design and discovery
|
journal
|
September 2017 |
Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses
|
journal
|
December 2002 |
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
|
journal
|
December 2013 |
Systematic Study of the Glutathione Reactivity of N -Phenylacrylamides: 2. Effects of Acrylamide Substitution
|
journal
|
September 2020 |
Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry
|
journal
|
March 2021 |
Target engagement and drug residence time can be observed in living cells with BRET
|
journal
|
December 2015 |
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complex
|
journal
|
July 2010 |
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
|
journal
|
February 2016 |
A quantitative analysis of kinase inhibitor selectivity
|
journal
|
January 2008 |
The Dark Kinase Knowledgebase: an online compendium of knowledge and experimental results of understudied kinases
|
journal
|
October 2020 |
Death-associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes
|
journal
|
June 2018 |
DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia
|
journal
|
October 2020 |
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
|
journal
|
October 2011 |
Hallmarks of Cancer: The Next Generation
|
journal
|
March 2011 |
The MPS1 Family of Protein Kinases
|
journal
|
July 2012 |
Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G 1 –S Checkpoint
|
journal
|
June 2018 |
TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers
|
journal
|
July 2017 |
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination
|
journal
|
December 2019 |
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
|
journal
|
February 2021 |
Mps1 kinase regulates tumor cell viability via its novel role in mitochondria
|
journal
|
July 2016 |
Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway
|
journal
|
November 2019 |
TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability: Effect of Mps1 inhibitor on hepatocellular carcinoma cells
|
journal
|
April 2017 |
Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer
|
journal
|
September 2016 |
Unmasking senescence: context-dependent effects of SASP in cancer
|
journal
|
June 2019 |
Systematic Study of the Glutathione (GSH) Reactivity of N -Arylacrylamides: 1. Effects of Aryl Substitution
|
journal
|
November 2015 |
High-throughput production of human proteins for crystallization: The SGC experience
|
journal
|
October 2010 |
XDS
|
journal
|
January 2010 |
Overview of the CCP 4 suite and current developments
|
journal
|
March 2011 |
Features and development of Coot
|
journal
|
March 2010 |
MolProbity : all-atom structure validation for macromolecular crystallography
|
journal
|
December 2009 |
Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement
|
journal
|
February 2018 |
Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2
|
journal
|
May 2021 |
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors
|
journal
|
January 2019 |
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
|
journal
|
December 2020 |